Literature DB >> 28326467

Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.

Natalia Kraeva1, Alexander Sapa1, James J Dowling2, Sheila Riazi3.   

Abstract

INTRODUCTION: Two potentially fatal syndromes, malignant hyperthermia (MH), an adverse reaction to general anesthesia, and exertional rhabdomyolysis (ER) share some clinical features, including hyperthermia, muscle rigidity, tachycardia, and elevated serum creatine kinase. Some patients with ER have experienced an MH event and/or have been diagnosed as MH susceptible (MHS). In order to assess the relationship between ER and MH further, we conducted a retrospective cohort study summarizing clinical and genetic information on Canadian patients with ER who were diagnosed as MHS. In addition, a systematic literature review was performed to compile further evidence on MH susceptibility and RYR1 and CACNA1S variants associated with rhabdomyolysis.
METHODS: Demographic, clinical, and genetic information was collected on Canadian MHS patients who presented with rhabdomyolysis. In addition, we performed a systematic review of the literature published during 1995-2016 on genetic screening of the RYR1 and CACNA1S genes in patients with ER.
RESULTS: Retrospective data on Canadian MHS patients with ER showed that ten out of 17 patients carried RYR1 or CACNA1S variants that were either known MH-causative mutations or potentially pathogenic variants. The systematic review revealed 39 different rare RYR1 variants, including 13 MH-causative/associated mutations and five rare potentially deleterious CACNA1S variants in 78% of patients with ER.
CONCLUSION: Findings from the Canadian patient cohort and the systematic review all signal a potential association between MH susceptibility and ER. The presence of MH-causative mutations and putative deleterious RYR1 variants in ER patients without a history of adverse anesthetic reactions suggests their possible increased risk for MH.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28326467     DOI: 10.1007/s12630-017-0865-5

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  11 in total

1.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

Review 2.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

3.  Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.

Authors:  Philip M Jones; Britney N Allen; Richard A Cherry; Luc Dubois; Kelly N Vogt; Salimah Z Shariff; Krista M Bray Jenkyn; Sheila Riazi; Duminda N Wijeysundera
Journal:  Can J Anaesth       Date:  2018-11-12       Impact factor: 5.063

4.  PharmGKB summary: very important pharmacogene information for CACNA1S.

Authors:  Katrin Sangkuhl; Robert T Dirksen; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000

Review 5.  Update on Congenital Myopathies in Adulthood.

Authors:  George Konstantinos Papadimas; Sophia Xirou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

6.  Intravenous dantrolene in hypermetabolic syndromes: a survey of the U.S. Veterans Health Administration database.

Authors:  Stanley N Caroff; Christopher B Roberts; Henry Rosenberg; Joseph R Tobin; Stacey Watt; Darlene Mashman; Sheila Riazi; Rosalind M Berkowitz
Journal:  BMC Anesthesiol       Date:  2022-09-19       Impact factor: 2.376

7.  Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series.

Authors:  Elena Zvaritch; Robyn Gillies; Natalia Kraeva; Maxime Richer; Heinz Jungbluth; Sheila Riazi
Journal:  Can J Anaesth       Date:  2019-02-19       Impact factor: 5.063

8.  A case report of malignant hyperthermia in a patient with myotonic dystrophy type I: A CARE-compliant article.

Authors:  Seon Woo Yoo; Seon Ju Baek; Dong-Chan Kim; A Ram Doo
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

9.  Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation.

Authors:  Hui J Wang; Chang Seok Lee; Rachel Sue Zhen Yee; Linda Groom; Inbar Friedman; Lyle Babcock; Dimitra K Georgiou; Jin Hong; Amy D Hanna; Joseph Recio; Jong Min Choi; Ting Chang; Nadia H Agha; Jonathan Romero; Poonam Sarkar; Nicol Voermans; M Waleed Gaber; Sung Yun Jung; Matthew L Baker; Robia G Pautler; Robert T Dirksen; Sheila Riazi; Susan L Hamilton
Journal:  Nat Commun       Date:  2020-10-09       Impact factor: 17.694

Review 10.  Inherited Neuromuscular Disorders: Which Role for Serum Biomarkers?

Authors:  Antonino Lupica; Vincenzo Di Stefano; Andrea Gagliardo; Salvatore Iacono; Antonia Pignolo; Salvatore Ferlisi; Angelo Torrente; Sonia Pagano; Massimo Gangitano; Filippo Brighina
Journal:  Brain Sci       Date:  2021-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.